820 related articles for article (PubMed ID: 32110880)
1. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases.
Sanchez-Rodriguez E; Egea-Zorrilla A; Plaza-Díaz J; Aragón-Vela J; Muñoz-Quezada S; Tercedor-Sánchez L; Abadia-Molina F
Nutrients; 2020 Feb; 12(3):. PubMed ID: 32110880
[TBL] [Abstract][Full Text] [Related]
2. The gut microbiome and cardiovascular disease: current knowledge and clinical potential.
Ahmad AF; Dwivedi G; O'Gara F; Caparros-Martin J; Ward NC
Am J Physiol Heart Circ Physiol; 2019 Nov; 317(5):H923-H938. PubMed ID: 31469291
[TBL] [Abstract][Full Text] [Related]
3. Probiotics, gut microbiome, and cardiovascular diseases: An update.
Dosh L; Ghazi M; Haddad K; El Masri J; Hawi J; Leone A; Basset C; Geagea AG; Jurjus R; Jurjus A
Transpl Immunol; 2024 Apr; 83():102000. PubMed ID: 38262540
[TBL] [Abstract][Full Text] [Related]
4. Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases.
Lau K; Srivatsav V; Rizwan A; Nashed A; Liu R; Shen R; Akhtar M
Nutrients; 2017 Aug; 9(8):. PubMed ID: 28796176
[TBL] [Abstract][Full Text] [Related]
5. The gut microbiota as a novel regulator of cardiovascular function and disease.
Battson ML; Lee DM; Weir TL; Gentile CL
J Nutr Biochem; 2018 Jun; 56():1-15. PubMed ID: 29427903
[TBL] [Abstract][Full Text] [Related]
6. Gut Microbiota and Heart, Vascular Injury.
Zeng C; Tan H
Adv Exp Med Biol; 2020; 1238():107-141. PubMed ID: 32323183
[TBL] [Abstract][Full Text] [Related]
7. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
Leclercq S; de Timary P; Stärkel P
Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
[TBL] [Abstract][Full Text] [Related]
8. [The gut microbiota, a new cardiovascular risk factor?].
Chong-Nguyen C; Duboc H; Sokol H
Presse Med; 2017; 46(7-8 Pt 1):708-713. PubMed ID: 28756077
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy.
Hsu CN; Hou CY; Hsu WH; Tain YL
Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371800
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiota, Atherosclerosis, and Therapeutic Targets.
Mantziaris V; Kolios G
Crit Pathw Cardiol; 2019 Sep; 18(3):139-142. PubMed ID: 31348074
[TBL] [Abstract][Full Text] [Related]
11. A Proinflammatory Gut Microbiota Increases Systemic Inflammation and Accelerates Atherosclerosis.
Brandsma E; Kloosterhuis NJ; Koster M; Dekker DC; Gijbels MJJ; van der Velden S; Ríos-Morales M; van Faassen MJR; Loreti MG; de Bruin A; Fu J; Kuipers F; Bakker BM; Westerterp M; de Winther MPJ; Hofker MH; van de Sluis B; Koonen DPY
Circ Res; 2019 Jan; 124(1):94-100. PubMed ID: 30582442
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic and Modulation of Microbiota: A New Paradigm?
Rizzatti G; Ianiro G; Gasbarrini A
J Clin Gastroenterol; 2018; 52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017():S74-S77. PubMed ID: 29912755
[TBL] [Abstract][Full Text] [Related]
13. Role of gut microbiota in atherosclerosis.
Jonsson AL; Bäckhed F
Nat Rev Cardiol; 2017 Feb; 14(2):79-87. PubMed ID: 27905479
[TBL] [Abstract][Full Text] [Related]
14. Intestinal Immunity and Gut Microbiota in Atherogenesis.
Yamashita T
J Atheroscler Thromb; 2017 Feb; 24(2):110-119. PubMed ID: 27928097
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
Haak BW; Prescott HC; Wiersinga WJ
Front Immunol; 2018; 9():2042. PubMed ID: 30250472
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
17. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation.
Elangovan A; Allegretti JR; Fischer M
Expert Opin Biol Ther; 2019 Dec; 19(12):1343-1355. PubMed ID: 31570017
[No Abstract] [Full Text] [Related]
18. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiome interventions in human health and diseases.
Nie P; Li Z; Wang Y; Zhang Y; Zhao M; Luo J; Du S; Deng Z; Chen J; Wang Y; Chen S; Wang L
Med Res Rev; 2019 Nov; 39(6):2286-2313. PubMed ID: 30994937
[TBL] [Abstract][Full Text] [Related]
20. Interaction between gut microbiome and cardiovascular disease.
Peng J; Xiao X; Hu M; Zhang X
Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
